Bain Capital Life Sciences Fund III, L.P. is 10% Owner at Kyverna Therapeutics, Inc. (KYTX). They have made 1 open-market trade across 1 company since 2024, most recently 2025-08-11.
CIK 0001875273
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $9.9M since 2024, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KYTX | BUY | 2024-02-12 | 2024-02-14 | $22.00 | $9.9M | -7.1% | +0.3% | -47.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.